/Investor DB

Advent Life Sciences — 2024 Investments

3 investments dated 2024 · listed companies and verified rows first · show all

Moximedmoximed.comSeries C · Aug 2024 · $50M

HealthtechFremont, US

Anton Clifford(Executive Officer)inJames Leech(Executive Officer)inChristopher Gleason(Executive Officer)inKevin K. Sidow(Executive Officer, Director)

BoardJoshua Makower(Director)

Board seatShahzad Malik· per SEC Form D

Co-investorsLightstone VenturesNew Enterprise Associates (NEA)Runway Growth CapitalGBS Venture Partners Ltd.Gilde HealthcareMorgenthaler+1 more

Argá Medtechargamedtech.comFeb 2024

Argá Medtech is developing a non-thermal cardiac ablation system based on a proprietary Pulsed Field Ablation (PFA) technology using sine wave energy and a proprietary catheter to treat atrial fibrillation and other heart arrhythmias.

HardwareHealthtechMedical Devices

Co-investorsHigh Tech GruenderfondsHTGFEarlybird Venture CapitalGilde Healthcare

Epitopeaepitopea.cominSeed · Oct 2024 · $31M

Epitopea develops off-the-shelf cancer vaccines targeting aberrantly expressed tumor-specific antigens using its proprietary CryptoMap platform.

AI & Machine LearningBiotechHealthtechMontreal, CA

Claude PerreaultPierre Thibault

Co-investorsCambridge Innovation CapitalCTI Life Sciences Fund L.P.adMare BioInnovationsFonds de solidarité FTQ

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.